問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Thoracic Medicine

更新時間：2023-09-19

吳沼漧
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

4Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳沼漧

List

24Cases

2020-09-15 - 2025-12-31

Phase III

Completed
A randomized, double-blind, double-dummy, parallel grouping, multi-center 24 to 52-week variable length trial designed to evaluate Budesonide, Glycopyrronium, and Formoterol Fumarate metered-dose inhalers (MDI) relative to Budesonide and Formoterol Fumarate MDI and Symbicort® pressure MDI, the efficacy and safety of adult and adolescent participants with poor asthma control (KALOS)

  • Condition/Disease

    Adults and adolescents with poor asthma control

  • Test Drug

    BGF MDI

Participate Sites
12Sites

Recruiting12Sites

2009-07-01 - 2010-07-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2013-07-01 - 2015-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2012-05-30 - 2013-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2010-08-30 - 2012-09-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2020-11-02 - 2024-04-30

Phase III

Completed
A phase 3, randomized, double-blind, placebo-controlled trial to evaluate the safety, efficacy, and tolerability of Brensocatib administered once a day to subjects with non-cystic fibrosis bronchiectasis for 52 weeks – ASPEN test

  • Condition/Disease

    Non-cystic fibrotic bronchiectasis

  • Test Drug

    Brensocatib (INS1007)

Participate Sites
7Sites

Recruiting7Sites

2012-05-01 - 2014-12-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2010-04-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2014-12-01 - 2018-12-31

Phase III

A randomised, double-blind, double dummy, chronic dosing (56 week) placebo-controlled, parallel group, multicentre, phase III study to evaluate the efficacy and safety of 3 doses of benralizumab (MEDI-563) in patients with moderateto very severe Chronic Obstructive Pulmonary Disease (COPD) with a history of COPD exacerbations (TERRANOVA)

  • Condition/Disease

    Chronic obstructive pulmonary disease

  • Test Drug

    Benralizumab

Participate Sites
8Sites

Terminated8Sites

2018-09-01 - 2022-03-31

Phase III

PONENTE: A multicenter, open-label, Phase 3b trial for adult patients with severe eosinophilic leukocyte asthma who are treated with high-dose corticosteroid inhalers, plus long-acting beta 2 agonists and oral corticosteroids for long-term treatment, to evaluate subcutaneously Efficacy and safety of 30 mg injection of Benralizumab for reducing oral corticosteroid dosage

  • Condition/Disease

    Severe eosinophilic leukocyte asthma

  • Test Drug

    Benralizumab

Participate Sites
8Sites

Recruiting8Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

郭漢彬
Taipei Medical University Hospital

Division of Thoracic Medicine

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB